Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 25;15(17):4270.
doi: 10.3390/cancers15174270.

Aggressive Prostate Cancer in Patients Treated with Active Surveillance

Yoichiro Tohi  1 , Takuma Kato  1 , Mikio Sugimoto  1
Affiliations
Review

Aggressive Prostate Cancer in Patients Treated with Active Surveillance

Yoichiro Tohi et al. Cancers (Basel). .

Abstract

Active surveillance has emerged as a promising approach for managing low-risk and favorable intermediate-risk prostate cancer (PC), with the aim of minimizing overtreatment and maintaining the quality of life. However, concerns remain about identifying "aggressive prostate cancer" within the active surveillance cohort, which refers to cancers with a higher potential for progression. Previous studies are predictors of aggressive PC during active surveillance. To address this, a personalized risk-based follow-up approach that integrates clinical data, biomarkers, and genetic factors using risk calculators was proposed. This approach enables an efficient risk assessment and the early detection of disease progression, minimizes unnecessary interventions, and improves patient management and outcomes. As active surveillance indications expand, the importance of identifying aggressive PC through a personalized risk-based follow-up is expected to increase.

Keywords: active surveillance; aggressive prostate cancer; favorable intermediate-risk prostate cancer; low-risk prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. He W., Goodkind D., Kowal P. An Aging World. [(accessed on 16 June 2023)];2015 Available online: https://www.census.gov/content/dam/Census/library/publications/2016/demo....
    1. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., Petros J.A., Andriole G.L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991;324:1156–1161. doi: 10.1056/NEJM199104253241702. - DOI - PubMed
    1. Neppl-Huber C., Zappa M., Coebergh J.W., Rapiti E., Rachtan J., Holleczek B., Rosso S., Aareleid T., Brenner H., Gondos A., et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: Additional diagnoses and avoided deaths. Ann. Oncol. 2012;23:1325–1334. doi: 10.1093/annonc/mdr414. - DOI - PubMed
    1. Resnick M.J., Koyama T., Fan K.H., Albertsen P.C., Goodman M., Hamilton A.S., Hoffman R.M., Potosky A.L., Stanford J.L., Stroup A.M., et al. Long-term functional outcomes after treatment for localized prostate cancer. N. Engl. J. Med. 2013;368:436–445. doi: 10.1056/NEJMoa1209978. - DOI - PMC - PubMed

LinkOut - more resources